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ABSTRACT
GPRC6Aisawidelyexpressed orphanGprotein–coupledreceptorthatsensesextracellularaminoacids,osteocalcin,anddivalentcations
in vitro. GPRC6A null (GPRC6A
 / ) mice exhibit multiple metabolic abnormalities including osteopenia. To investigate whether the
osseousabnormalitiesareadirectfunctionofGPRC6Ainosteoblasts,weexaminedthefunctionofprimaryosteoblastsandbonemarrow
stromal cell cultures (BMSCs) in GPRC6A
 /  mice. We confirmed that GPRC6A
 /  mice exhibited a decrease in bone mineral density
(BMD) associated with reduced expression of osteocalcin, ALP, osteoprotegerin, and Runx2-II transcripts in bone. Osteoblasts and BMSCs
derived from GPRC6A
 /  mice exhibited an attenuated response to extracellular calcium-stimulated extracellular signal-related kinase
(ERK) activation, diminished alkaline phosphatase (ALP) expression, and impaired mineralization ex vivo. In addition, siRNA-mediated
knockdown of GPRC6A in MC3T3 osteoblasts also resulted in a reduction in extracellular calcium-stimulated ERK activity. To explore the
potential relevance of GPRC6A function in humans, we looked for an association between GPRC6A gene polymorphisms and BMD in a
sample of 1000 unrelated American Caucasians. We found that GPRC6A gene polymorphisms were significantly associated with human
spine BMD. These data indicate that GRPC6A directly participates in the regulation of osteoblast-mediated bone mineralization and may
mediate the anabolic effects of extracellular amino acids, osteocalcin, and divalent cations in bone.  2010 American Society for Bone
and Mineral Research.
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Introduction
G
PRC6A is a recently identified member of family C of G
protein–coupled receptors (GPCRs) that senses extracellular
cations, osteocalcin, and amino acids.
(1–4) Transcripts for GPRC6A
are expressed in many tissues and organs, including lung,
liver, spleen, heart, kidney, blood vessels, skeletal muscle,
testis, brain, and bone.
(1–5) Consistent with its broad expression,
ablation of GPRC6A is associated with multiple abnormalities,
including glucose intolerance, hepatic steatosis, abnormal
steroid biogenesis, and osteopenia, suggesting that GPRC6A
may directly or indirectly regulate anabolic responses in multiple
organs.
(6)
Bone has been proposed to be a special tissue compartment
where the combination of calcium, osteocalcin, and amino acids
might constitute important extracellular signals regulating bone
formation.
(4) While osteoblast-mediated bone formation is
coupled to osteoclast-mediated bone resorption through the
production by osteoblastic stromal cells of osteoprotegerin
(OPG) and receptor activator of NF-kB ligand (RANKL),
(7) there is
also emerging evidence for reverse coupling by factors released
from osteoclast-mediated degradation of mineralized bone
matrix, such as amino acids and calcium, that act on osteoblasts
to fill in the resorptive cavity.
(8) Indeed, several mouse models
with a primary increase in osteoclast-mediated bone resorption,
including OPG and calcitonin null mice,
(9,10) have a secondary
increase in osteoblast-mediated bone formation. Conversely,
osteopetrotic disorders caused by a primary decrease in bone
resorption are often accompanied by decreased bone formation,
possibly through the loss of signals from osteoclasts.
(8) In
addition, high ambient Ca
2þ concentrations (in the range of 8 to
40mM) and amino acids are present at sites of bone
resorption,
(11) and a positive correlation exists between lumbar
and femoral bone mass and the intake of protein and calcium.
(12)
Since dietary protein-derived chemical signals may be derived
from their metabolism into free amino acids,
(13) circulating levels
of amino acids and calcium also may modulate signaling
pathways in bone. Finally, both osteoblasts and osteoclasts
respond to extracellular calcium in vitro through a putative
extracellular amino acid and calcium-sensing GPCR.
(11,14,15)
ORIGINAL ARTICLE J JBMR
Received in original form June 29, 2009; revised form September 17, 2009; accepted October 22, 2009. Published online October 26, 2009.
Address correspondenceto:MinPi,PhD,orLDarryl Quarles,MD,UniversityofTennesseeHealthScienceCenter,956CourtAvenue,ColemanSuit, 226,Memphis, TN,
38163, USA. E-mail: mpi@uthsc.edu or dquarles@uthsc.edu
Journal of Bone and Mineral Research, Vol. 25, No. 5, May 2010, pp 1092–1102
DOI: 10.1359/jbmr.091037
 2010 American Society for Bone and Mineral Research
1092GPRC6Aisexpressedinosteoblasts,
(4,16)butitsfunctioninbone
is not clear. Preliminary characterization of the skeleton of
GPRC6A
 /  mice indicates that loss of this receptor is associated
with decreased bone mineral density (BMD) and impaired
mineralization of bone,
(6) but the presence of other abnormalities
confounded the ability to ascertain the direct and indirect effects
of GPRC6A on skeletal function. To determine if GPRC6A is a
potential candidate for the purported extracellular calcium-
sensing receptor in osteoblasts, we performed a more detailed
assessment of the skeletal phenotype of GPRC6A
 /  mice,
examined the function of primary osteoblasts and bone marrow
stromal cells derived from these mutant mice ex vivo, and
evaluated whether polymorphisms in GPRC6A are associated with
skeletal abnormalities in humans by a gene association analysis.
Materials and Methods
GPRC6A knockout mice
The GPRC6A-deficient mouse model was created by replacing
exon2oftheGPRC6Agenewiththehygromycinresistancegene,
as described previously.
(6) Mice were maintained and used in
accordance with recommendations of theNational Research
Council’s (1985) Guide for the Care and Use of Laboratory Animals
(DHHS Publication NIH 86-23, Institute on Laboratory Animal
Resources, Rockville, MD) and following guidelines established
by the University of Kansas Medical Center Institutional Animal
Care and Use Committee.
RT-PCR and real-time RT-PCR
Reverse-transcriptase polymerase chain reaction (RT-PCR) was
performed using two-step RNA PCR (Perkin-Elmer, Waltham, MA,
USA). In separate reactions, 2.0mg of DNase-treated total RNA
was reverse transcribed into cDNA with the respective reverse
primers specified below and Moloney murine leukemia virus
reverse transcriptase (Life Technologies, Inc., Rockville, MD, USA).
Reactions were carried out at 428C for 60 minutes followed by
948C for 5 minutes and 58C for 5 minutes. The products of first-
strand cDNA synthesis were directly amplified by PCR using
AmpliTaq DNA polymerase (Perkin-Elmer). The primer sets used
to amplify various gene transcripts with intron spanning are as
follows: mGPRC6A.189F: CGGGAT CCAGACGACCACAAATCCAG
and mGPRC6A.539R: CCAAGCTTGATTCATAACTCACCTGTGGC;
mALP.905F: AACCCAGACACAAGCATTCC and mALP.1458R:
CTGGGCCTGGTAGTTGTTGT, G3PDH.F143: GACCCCTTCATTGAC-
CTCAACTACA; and G3PDH.R1050: GGTCTTACTCCTTGGAGGC-
CATGT for control RNA loading.
For quantitative real-time RT-PCR assessment of bone marker
expression, we isolated and reverse transcribed 2.0mg of total
RNA from the long bones of 8-week-old mice as described
previously.
(17)PCRreactionscontained100ngoftemplate(cDNA
or RNA), 300nM each of forward and reverse primer, and 1  iQ
SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) in 50mL.
Samples were amplified for 40 cycles in an iCycler iQ Real-Time
PCR Detection System (Bio-Rad) with an initial melt at 958C for
10 minutes, followed by 40 cycles of 958C for 15 seconds and
608C for 1 minute. PCR product accumulation was monitored at
multiple points during each cycle by measuring the increase in
fluorescencecausedbythebindingofSybrGreenItodsDNA.The
threshold cycle (Ct) of tested-gene product from the indicated
genotype was normalized to the Ct for cyclophilin A. Dissociation
analysis was used to confirm the presence of a single transcript
and lack of primer-dimer amplification in all PCR reactions.
PIXImus bone densitometer analysis, X-ray, and bone
histology
PIXImus bone densitometer analysis, X-ray, and bone histology
Bone mineral density (BMD) values of whole skeletons and femurs
were assessed at 6, 8, 12, and 16 weeks of age using a PIXImus
bone densitometer (Lunar Corp., Madison, WI, USA) as described
previously.
(18) Femurs were dissected free of muscle and X-rayed
w i t haF a x i t r o nm o d e lM X - 2 0s p e c i m e nr a d i o g r a p h ys y s t e m
(Faxitron X-Ray Corp., Lincolnshire, IL, USA). In addition, length and
width (measured at 50% of the femur length) were assessed in
isolated femora. Skeletons of mice were prelabeled twice with
calcein (Sigma C-0875, 30mg / go fb o d yw e i g h t ;S i g m a lC h e m i c a l
Company, St. Louis, MO, USA) by intraperitoneal injection at 8 and
3 days prior to sacrifice. Tibiae and femora were removed from
8- and 16-week-old mice, fixed in 70% ethanol, prestained in
Villanueva stain, and processed for methyl methacrylate embed-
ding. Then 10-mm Villanueva-prestained sections were evaluated
underfluorescentlight,asreportedpreviouslybyourlaboratory.
(18)
Micro-computed tomographic (mCT) analysis
The distal femoral metaphyses were scanned using a mCT 40
device (Scanco Medical AG, Wayne, PA, USA); 167 slices of the
metaphysis under the growth plate, constituting 1.0mm in
length, were selected. The 3D images were generated using the
following values for a gauss filter (s¼0.8, support 1) and a
threshold of 275. A 3D image analysis was performed to
determine bone volume (BV/TV), trabecular number (Tb.N),
trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp).
Cortical bone was measured on the midshaft region of cortical
bone in 50 slices of the diaphysis, constituting 0.3mm in length.
The mean cortical thickness (Ct.Th) was determined at eight
different points on the cortical slice.
Primary bone marrow stromal cells and osteoblastic cells
culture
The femora and tibiae from 8-week-old wild-type and GPRC6A
 / 
mice were dissected, the ends of the bones were cut, and marrow
was flushed out with 2mL of ice-cold a modified essential
medium (a-MEM) containing 10% fetal bovine serum (FBS) by
using a needle and syringe. A suspension of bone marrow cells
was obtained by repeated aspiration of the cell preparation
through a 22G needle, and nucleated cells were counted with a
hemocytometer. Cells were seeded into 6-well plates at a density
of 3 10
7cells/mL and cultured for 3 days in a-MEM supple-
mented with 10% FBS, 100kU/L of sodium penicillin G, and
100mg/L of streptomycin sulfate in a humidified incubator with
5% CO2 and 95% air at a temperature of 378C. On day 3, all
nonadherent cells were removed with the first medium change,
and then the adherent cells [representing bone marrow–derived
mesenchymal stem cells (BMSCs)] were grown for additional
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quiescence, the cells were stimulated for 5 minutes with calcium,
NPS-R568, and arginine at the concentrations indicated.
We used modifications of a nonenzymatic method for
obtaining the osteoblastic cell lines.
(19) A fragment of the
frontal and/or parietal bone from the single calvarium was
aseptically removed from a 3- to 7-day-old mouse. Suture lines
and endosteum were dissected away, and the bone fragment
was placed in a culture dish. One or two metal strips were
positioned on the endocranial surface and incubated for 3 to 4
days in DMEM nutrient mixture F-12 (Invitrogen, Carlsbad, CA,
USA) containing 10% (v/v) FBS, 100kU/L of sodium penicillin G,
and 100mg/L of streptomycin until the outgrowth of osteo-
blasts.Themetalstripswereremoved,andthecellswereallowed
to grow until approximately 60% confluent. The cells were
subcultured and propagated by incubation in a-MEM (Invitro-
gen) containing 10% FBS, 100kU/L of sodium penicillin G,
100mg/L of streptomycin, and 50mg/mL ascorbic acid in a
humidified atmosphere of 5% CO2 and 95% air at 378C.
Agonist stimulation and Western blotting
Agonist stimulation was performed in quiescent cells. Quiescence
was achieved in subconfluent cultures by removing the medium
and washing with Hank’s balanced salt solution (Invitrogen) to
remove residual serum, followed by incubation for an additional
24 hours in serum-free medium. After agonist treatment at the
specified concentrations and durations, cells were washed twice
with ice-cold PBS and scraped into 250mL of lysis buffer (25mM
HEPES, pH 7.2, 5mM MgCl2, 5mM EDTA, 1% Triton X-100, and
0.02tablet/mL of protease inhibitor mixture). Equal amounts of
lysates were subjected to 10% SDS-PAGE and transferred onto
Immun-BlotPVDF(Bio-Rad).Forphospho-ERK,thephospho-ERK1/
2levelsweredeterminedbyimmunoblottingusinganti-phospho-
ERK1/2 mitogen-activated protein kinase antibody (Cell Signaling
Technology Inc., Beverly, MA, USA). To confirm that variations in
the amount of ERK did not contribute to stimulated ERK activity,
we used an anti-ERK1/2 mitogen-activated protein kinase anti-
body (Cell Signaling Technology, Inc.) to measure ERK levels for
control protein loading. The signals were quantified by densito-
metric scanning (FotoDyne, Hartland, WI, USA).
Mineralization assay
The formation of in vitro mineralization nodules was determined
by alizarin red S histochemical staining.
(15) The 14-day cultured
cells in the a-MEM containing 10% FBS, 100kU/L of sodium
penicillin G, 100mg/L of streptomycin sulfate, 50mg/mL of
ascorbic acid, and 4mM of arginine were fixed for 24 hours in a
solution of 10% Formalin, methanol, and water (1:1:1.5); the
fixative was removed; and the fixed cells and matrices were
stained for 15 minutes with a 2% (w/v) solution of alizarin red S
at pH 4.0. The stained samples were washed three times with
water and then air-dried.
Immunohistochemistry for osteocalcin (OC) and
measurement of aklaline phosphatase (ALP) activity
Anti-osteocalcin antibody was obtained from Dr Larry Fisher
(NIDCR, National Institutes of Health). After deparaffinization and
rehydration, the bone sections were immersed in 3% hydrogen
peroxide to quench endogenous peroxidase and further
digested with 1mg/mL trypsin for 30 minutes at 378C. Sections
then were blocked with 1% bovine serum albumin at room
temperature for 2 hours. The primary antibodies were added to
the sections and incubated overnight at 48C. After washing, the
sections were coated with biotinylated second antibody (Vector
Laboratories Burlingame, CA, USA) at a dilution of 1:200 and then
incubated at room temperature for 60 minutes. The sections
were washed again and incubated with the ABC reagent (Vector
Laboratories, Burlingame, CA, USA) at room temperature for 60
minutes.The3,3’-diaminobenzidinesubstratewasusedtovisualize
immunoreaction sites. Sections were counterstained with hema-
toxylin and mounted on glass slides. Negative controls were
obtained by substituting the primary antibody with normal IgG.
Alkaline phosphatase (ALP) activity was detected by an
enzyme-substrate assay in frozen sections of bone. Briefly, fresh
nondecalcified spines from 8-week-old wild-type and GPRC6A
knockout mice were dissected and embedded with Optimum
Cutting Temperature (OCT, Sakura Finetek, USA, Inc., Torrance,
CA, USA) medium. ALP activity was detected in 12-mm-thick
cryostat sections at alkaline pH by adding ALP substrate 4-nitro
blue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl phos-
phate (BCIP) directly on the slides according to the manufac-
turer’s instructions (Roche Applied Science, Indianapolis, IN,
USA). Endogenous ALP activity was visualized as a purple-blue
color reaction with methyl green (nuclei) counterstain.
In situ hybridization for osteocalcin mRNA expression
A mouse osteocalcin cDNA plasmid, EcoRI/Pst I subclone inserted
into pSP65, was obtained from Dr Stephen Harris (University
of Texas Health Science Center, San Antonio, TX, USA). A
digoxigenin (DIG)–labeled cRNA probe was prepared by using
the RNA Labeling Kit (Roche Applied Science). To make the
antisense probe, a partial mouse osteocalcin cDNA (0.5kb) was
cleaved by Hind III and labeled with Sp6 polymerase. Sections of
the tibia from a 8-week-old mouse were dewaxed, rehydrated,
fixed with 4% paraformaldehyde, treated with 2% glycine and
proteinase K, acetylated using an acetic anhydride–TEA solution,
and then hybridized with a DIG-labeled probe. After washing the
sections twice with 50% formamide, 5% saline sodium citrate,
and 5% SDS for 30 minutes at 708C and once with 50%
formamide and 2% saline sodium citrate for 30 minutes at 658C,
we incubated them with antibody to digoxigenin conjugated
with alkaline phosphatase and then with nitro blue etrazolium/
4-bromo-5-chloro indolylphosphate, which yields a purple-blue
color. We also counterstained the sections with methyl green
(nuclei). The hybridization signals were photographed with a
Nikon E800 microscope (Nikon, Melville, NY, USA) and a
MagnaFire camera (Optronics, Muskogee, OK, USA).
Serum and urine biochemical measurements
Serum was collected using a retro-orbital bleeding technique.
For urine samples collection, mice were placed in metabolic
cages (Hatteras Instrument Cary, NC, USA), and urine was
collected for 24 hours. The urine volume was measured before
storage at  708C.
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cresolphthalein-binding method, and phosphorus was measured
by the phosphomolybdate–ascorbic acid method.
(18) Serum
tartrate-resistant acid phosphatase (TRACP) was assayed with the
ELISA-based SBA Sciences mouseTRAP assay (Immutopics, Inc., San
Clemente, CA, USA). Serum parathyroid hormone (PTH) and 1,25-
dihydroxyvitamin D were measured with an Immunodiagnostic
Systems device (Immunodiagnostic Systems, Ltd., Scottsdale, AZ,
USA). Serum Fgf23 levels were measured using an FGF-23 ELISA kit
(Kainos Laboratories, Inc., Tokyo, Japan) following the manufac-
turer’s protocol. Creatinine was measured by the colorimetric
alkaline picrate method (Sigma Kit 555). Urinary protein and
deoxypridinolme (Dpd) were measured by Bio-Rad and Metra
Biosystems (Hercules, San Diego, CA, USA) devices, respectively.
siRNA transfection
Two siRNAs (siRNA.m1638: CCAACACAGCTGTTGCTAT and siR-
NA.m2553: GCAGAAGACTAACACCAAA) specific for marine
GPRC6A (GenBank Accession Number NM_153071), identified
using the ‘‘siRNA Target Finder’’ at the Web site (www.ambion.-
com/techlib/misc/siRNA_finder.html), were used as a template for
synthesizing siRNA. Double-stranded siRNA was synthesized from
DNA oligonucleotides using the Silencer siRNA construction kit
(Ambion,Austin,TX,USA)accordingtomanufacturer’sinstructions.
For transfection, MC3T3 cells were plated at a density of
1.0 10
4cellsperwellina6-welldishandgrownovernight.Cells
were transiently transfected with 25nM of siRNA using 4mLo f
Lipofectamine 2000 (Invitrogen) for 4 hours, after which growth
medium was replaced. Then, 48 hours after transfection, cells
were quiescence overnight and then stimulated by 10mM of
calcium for 5 minutes and lysed for Western blot analysis.
Scrambled siRNA (Select Negative Control 1 siRNA, Ambion) was
used as negative control.
Study populations and genotyping
The 1000 unrelated American Caucasians of European origin
studied were identified from our established and expanding
genetic repertoire at UMKC. Signed informed-consent docu-
ments were obtained from all study participants before they
entered the study. The population genetic research on GPRC6A
was approved by the Institutional Review Board. The inclusion
and exclusion criteria are the same as those described
elsewhere.
(20) The basic characteristics of the studied subjects
are listed in Supplemental Table 1. Briefly, the sample includes
251elderlymen(agerangeatrecruitment52.9to87.9years),250
younger men (age range at recruitment 19.1 to 49.9 years),
250 postmenopausal women (age range at recruitment 54.3 to
80.6 years), and 249 premenopausal women (age range at
recruitment 19.2 to 53.2 years). Area BMD (g/cm
2) at the spine
and hip region was measured by dual-energy X-ray absorptio-
metry (DXA) with Hologic QDR 4500W densitometers (Hologic,
Inc., Bedford, MA, USA). The scanners were calibrated daily. The
coefficient of variation (CV) values of the DXA measurements
wereabout1.98%and1.87%forspineandhipBMD,respectively.
The nine single-nucleotide polymorphisms (SNPs) of interest in
vicinity of or inside the GPRC6A gene were genotyped successfully
with the Affymetrix GeneChip human mapping 500K array set
(Affymetrix, Inc., Santa Clara, CA, USA) as part of the large-scale
genotyping project. The genotyping was performed at the
Vanderbilt Microarray Shared Resource at Vanderbilt University
Medical Center (Nashville, TN, USA) using the standard protocol
recommended by the manufacturer. The genotyping procedure is
detailed elsewhere.
(20) The average per-SNP call rate of these nine
SNPs across the 1000 subjects is 99.4% (97.2% to 99.9%).
Statistical analysis
We evaluated differences between groups by one-way
analysis of variance. All values are expressed as means SEM.
All computations were performed using the Statgraphic
Statistical Graphics System (STSC, Inc., Rockville, MD, USA).
The Hardy-Weinberg equilibrium (HWE) test and linkage
disequilibrium(LD)plottingoftheinterestedSNPswereperformed
using the Haploview 4.1 (Broad Institute, Cambridge, MA) .
(21) The
default option ‘‘confidence intervals’’ in Haploview 4.1 was used to
define LD blocks.
(22)Before performing the marker-trait association
analysis, parameters such as age, age
2,s e x ,a g e / a g e
2-by-sex
interaction, height, and weight were tested for their associations
with BMD at the spine and hip; then the significant (p .05) terms
were included as covariates to adjust the raw BMD values for
subsequent analyses. All marker-trait association analyses were
performed using association tests implemented in HelixTree 5.3.1
(Golden Helix, Bozeman, MT, USA). To circumvent the problem of
false-positive results incurred by multiple testing, the SNPSpD
program developed by Nyholt was used to establish the
experiment-wise significance threshold needed to keep the type
I error rate less than 5%, considering the redundancy of
information provided by SNPs that were in LD.
(23)
Results
Skeletal imaging
By X-ray analysis, we observed no significantly gross develop-
mental abnormalities in the skeleton (Fig. 1A). Consistent with
prior reports,
(6) BMD as assessed by dual-energy X-ray
absorptrometry (DEXA) was significantly lower in 16-week-old
GPRC6A
 /  mice compared with wild-type mice (Fig. 1B). We
observedno difference infemur length(Fig. 1C,D),butthere was
a significant reduction in femur width between GPRC6A
 /  and
wild-type mice (Fig. 1C, E). In addition, we found that BMD was
reduced by mCT in both the metaphyseal area, which
predominately consists of trabecular bone, and the midshaft
region, which is composed of cortical bone (Fig. 1F). These
differences were not due to effects of a mixed genetic
background because these animals were crossed onto C57BL/
6 mice for more than six generations. There were no
demonstrable changes, however, in bone structural parameters,
including bone volume (BV/TV) and cortical thickness (Ct.Th),
between GPRC6A
 /  and wild-type mice, as assessed by mCT,
suggesting that the decreased BMD was not due to structural
changes in bone architecture.
Biomarkers/immunohistochemistry/gene expression
We found no evidence for GPRC6A effects on osteoclast function.
In this regard, the osteoclastic marker tartrate-resistant acid
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type and GPRC6A
 /  mice (Table 1), consistent with our prior
findings that neither urinary Dpd/creatinine ratio nor serum
TRACP levels were different between GPR6CA
 /  and GPR6CA
þ/þ
mice.
(6) Tobetter understand the effect ofGPRC6A onosteoblasts,
we examined gene expression profiles of whole-bone samples
from GPRC6A
 /  mice. Assessment of expression of osteoblast
markers in bone from 16-week-old GPRC6A
 /  mice revealed
reductions in osteocalcin, ALP, osteoprotegerin,a n dRunx2-II
message levels compared with wild-type mice by real-time RT-
PCR (Table 1), consistent with a reduction in mineral apposition
rates, as reported previously.
(6) We also confirmed by in situ
hybridization and immohistochemical staining that osteocalcin
expression (Fig. 2A–D)a n dALP activity (Fig. 2E, F) were reduced in
bonefrom16-week-oldGPRC6A
 / mice.Thechondrocytemarker
ColII and adipocyte markers aP2 and Lp1 were not significantly
different between wild-type and GPRC6A
 /  mice (Table 1).
Impaired extracellular calcium response in BMSCs and
calvarial-derived osteoblastic cells cultures from
GPRC6A
 /  mice
To explore whether the observed skeletal abnormalities are due
to a primary osteoblastic abnormality owing to loss of GPRC6A in
Fig. 1. Characterization of the bone phenotype of GPRC6A
 /  mice. (A) X-ray appearance for GPRC6A
þ/þ and GPRC6A
 /  mice at 16 weeks of age. (B)
ComparisonofthetotalBMDanalysisbyPIXImusanalysisinGPRC6A
þ/þandGPRC6A
 / miceatagesrangingfrom6to16weeks.(C)Abnormalitiesinfemur
bone of GPRC6A
 /  mice by X-ray. (D, E) Comparison of femur length (D) and femur width (E)i nGPRC6A
þ/þ and GPRC6A
 /  mice at 16 weeks of age. ( F)
Comparison of the structure and BMD of the femur as assessed by mCT scanning in 16-week-old GPRC6A
þ/þ and GPRC6A
 /  mice. Data represent the
mean SEM from 6 to 10 mice in each group.
 
Significant difference from GPRC6A
þ/þ and GPRC6A
 /  mice at p<.05.
Table 1. Gene Expression Profile in Bone From GPRC6A
þ/þ and GPRC6A
 /  Mice
Gene Accession number GPRC6A
þ/þ GPRC6A
 / 
ALP NM_007431 0.493 0.096 0.194 0.0045
a
Osteocalcin NM_007541 1.101 0.068 0.411 0.1
a
Osteoprotegerin MMU94331 0.0755 0.021 0.0159 0.0045
a
Runx2-II NM_009820 0.156 0.034 0.0563 0.0061
a
Osterix AF184902 0.00187 0. 00078 0. 00136 0. 00047
RANKL NM_011613 0.000987 0.00011 0.00124 0.00037
TRACP NM_007388 0.793 0.188 0.742 0.12
ColII NM_031163 0.457 0.219 0.186 0.056
aP2 NM_024406 1.229 0.305 1.624 0.342
LpI NM_008509 0.0803 0.0149 0.118 0.054
Data are mean SEM from 8-week-old mice. Values are expressed relative to the housekeeping gene cyclophilin A. ALP¼alkaline phosphatase;
RANKL¼receptor activator for nuclear factor kB ligand; TRACP¼tartrate-resistant acid phosphatase; aP2¼adipocyte fatty acid–binding protein 2;
ColII¼collagen type II; and Lpl¼lipoprotein lipase.
aDenotes significant difference between GPRC6A
þ/þ and GPRC6A
 /  mice at p<.05.
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and arginine of cultured of bone marrow stromal cell cultures
(BMSCs) and calavarial osteoblasts obtained from wild-type
and GPRC6A
 /  mice (Fig. 3). In both BMSCs and primary
osteoblasts, we observed a reduced ability of extracellular
calcium to stimulate ERK activity in GPRC6A
 /  mice compared
with wild-type cells (approximately 50% reduction; Fig. 3A, B). In
addition, a receptor allosteric modulator, the calcimimetic NPS-
568, and the amino acid receptor ligand L-arginine both had an
attenuated ERK activation in BMSCs and primary osteoblasts
obtained from GPRC6A
 /  mice compared with wild-type cells
(Figs. 3C, D).
To further evaluate osteoblast dysfunction in GPRC6A
 /  mice,
we examined the impact of loss of GPRC6A on the capacity of
cultured osteoblasts and BMSCs to undergo differentiation in
vitro, as assessed by culture duration–dependent changes in
alkaline phosphatase expression and activity. We found that
wild-type osteoblasts and BMSC cultures increased alkaline
phosphatase expression and activity during differentiation, but
thisincreasewasattenuatedinGPRC6A
 / cells(Fig.4A,B).These
results are consistent with the gene expression data by real-time
RT-PCR (Table 1) and immohistochemical staining (Fig. 2E, F)i n
intact bone. Moreover, the addition of arginine increased
mineralization in wild-type BMSC cultures but not in GPRC6A
 / 
cells(Fig.4C).These data indicate that thelack ofGPRC6Aimpairs
the ability of osteoblasts to sense calcium and amino acids as
well as their ability to undergo differentiation and form a
mineralized extracellular matrix.
Response of osteoblastic cell line MC3T3 to extracellular
calcium through GPRC6A
To confirm the role of GPRC6A as a relevant calcium- and amino
acid–sensing receptor, we examined the MC3T3 clonal osteo-
blastic cell line, which is known to express a putative calcium-
sensing receptor.
(4,24) We examined the function of GPRC6A by
siRNA-mediated knockdown in MC3T3 osteoblasts. We trans-
fected MC3T3 cells with either GPRC6A siRNA.m2563 or
siRNA.m1638. Mock-transfected cells and transfected cells with
a random negative control siRNA plasmid were used as the
control. Transfected MC3T3 cells GPRC6A siRNA.m2563 and
siRNA.m1638 successfully downregulated the levels of mRNA
expression of GPRC6A in MC3T3 cells compared with mock-
transfected cells and negative-control siRNA-transfected cells by
RT-PCR analysis (Fig. 5A). In addition, the activation of phospho-
ERK stimulated by extracellular calcium in MC3T3 cells was
significantly decreased by both transfected GPRC6A siR-
NA.m2563 and siRNA.m1638 (reduced approximately 50% and
97%, respectively; Fig. 5B). These results suggest that endogen-
ous GPRC6A accounts for the effects of extracellular calcium in
stimulating ERK phosphorylation.
Association of GPRC6A polymorphisms with spine and hip
BMD
Next, we performed a gene association analysis to test whether
GPRC6Agenepolymorphisms areassociated withthe variationin
human BMD.
(25) Nine SNPs located from 21kb downstream to
Fig. 2. Decreased osteocalcin expression and ALP activaties in GPRC6A
 /  mice. (A, B) Comparison of osteocalcin message expression by in situ
hybridizationinthefemoraofGPRC6A
þ/þ(A)andGPRC6A
 / mice(B).(C,D)Comparisonofosteocalcinexpressionbyimmunohistochemistryinthefemora
of GPRC6A
þ/þ (C) and GPRC6A
 /  mice (D). (E, F) Comparison of ALP activity in the cryostat sections of fresh nondecalcified spines from GPRC6A
þ/þ (E) and
GPRC6A
 /  mice ( F). Right panels are enlarged view from left panels. The techniques for in situ, immunohistochemistry and measurement of alkaline
phosphatase activity are described under ‘‘Materials and Methods.’’
DELETION OF GPRC6A CAUSES OSTEOPENIA Journal of Bone and Mineral Research 1097Fig. 3. Decreasedresponseto extracellularcalcium,NPS-R568, andaminoacid in BMSCsor osteoblastsfrom GPRC6A
 /  mice.(A, B) Bonemarrow stromal
cell cultures (BMSCs) and osteoblasts from GPRC6A
 /  mice displayed impaired responses to extracellular calcium-mediated ERK activation. (C) ERK
activation in response to the calcimimetic NPS-R568 also was impaired in BMSCs derived from GPRC6A
 /  mice. (D) Osteoblasts derived from GPRC6A
 / 
mice also showed impaired ERK activation in response to the amino acid arginine. ERK phosphosphorylation was assessed by Western blot analysis using
an anti-phospho-ERK antibody. Data represent three to four independent experiments.
Fig. 4. CharacterizationoftemporalmaturationalsequenceinosteoblastsorBMSCsfromGPRC6A
þ/þandGPRC6A
 / mice.(A)RT-PCRofalkalineALPfrom
4- and 10-day cultured cells derived from 8-week-old GPRC6A
þ/þ and GPRC6A
 /  calvaria. (B) ALP activity. The GPRC6A
 /  BMSCs had significantly lower
ALP activityat days10and14ofculturecomparedwithage-matchedwild-typemice.(C)Quantificationofmineralization. AlizarinredS wasextractedwith
10% cetylpyridinium chloride and quantified as described under ‘‘Materials and Methods.’’ Data represent the mean SEM from three to four
independent experiments.
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association with hip and spine BMD variation in the human
subjects studied. All nine SNPs are in HWE (p>.01) with minor
allelefrequency (MAF) greater than 5%. The basic information on
these SNPs is shown in Table 2.
Four SNPs, rs686708, rs571296, rs6938235, and rs17078405,
showed nominal significant associations with hip BMD (p<.05;
Table 2), but these associations became nonsignificant after
multiple-testing correction (significance-threshold p values were
set at .0074 by the program SNPSpD based on Nyholt’s
method
(23)). All nine SNPs showed nominal significant associa-
tions with spine BMD (p<.05; Table 2), but after multiple-testing
correction (threshold p¼.0074), only the association of SNPs
rs686708 and rs571296 with spine BMD remained significant
(p¼.0010 and p¼.0068, respectively).
For the SNP rs686708 (A/G), which showed the strongest
evidence of association with spine BMD, its allele A was
associated with lower spine BMD values in the studied subjects.
The subjects with the AA or AG genotypes had significant lower
spine BMD values than those with the GG genotype (raw spine
BMD values were 1.016, 1.032, and 1.055g/cm
2 for the AA, AG,
and GG genotypes, p¼.029), showing an allele dose effect of
0.02g/cm
2 lower spine BMD value per copy of the A allele. For
the SNP rs571296 (A/G), its minor allele G was associated with
lower spine BMD values. Subjects with the GG or AG genotypes
had significant lower spine BMD values than those with the
AA genotype (raw spine BMD values were 1.061, 1.037, and
1.019g/cm
2for AA, AG, and GG genotypes, p¼.032), showingan
allele dose effect of 0.021g/cm
2 lower spine BMD value per copy
of the G allele. Linkage disequilibrium (LD) analysis based on the
Fig. 5. Knockdown of endogenous GPRC6A expression in cultured osteoblastic MC3T3 cells represses to response to extracellular calcium. (A) GPRC6A
mRNA levels were analyzed by RT-PCR analysis in cultured osteoblastic MC3T3 cells transfected with indicated siRNAs for 48 hours. (B, C) siRNAs mediated
knockdown of GPRC6A-inhibited extracellular calcium-stimulated phospho-ERK activation in cultured osteoblastic MC3T3 cells. Phospho-ERK levels were
analyzed by Western blot analysis in cells transfected with indicated siRNA for 48 hours and then quiescent and stimulated with extracellular calciuma s
indicated under ‘‘Materials And Methods.’’ A minimum of three independent experiments was performed for each agonist and cell model. Panel B is a
representative response from a single experiment, and panel C shows the mean SEM of the changes in band intensity from three separate experiments.
Table 2. Associations of the Analyzed GPRC6A SNPs With Hip and Spine BMD
a
No. SNP name Position (bp) Role
Major/minor
alleles MAF
a
p Value,
b
hip BMD
p Value,
b
spine BMD
1 rs686708 117198376 Downstream A/G 0.453 .0280 .0010
2 rs571296 117199251 Downstream A/G 0.344 .0231 .0068
3 rs587771 117212212 Downstream G/T 0.205 .9168 .0077
4 rs6924002 117220916 CDS A/T 0.307 .0713 .0408
5 rs17078383 117230654 Intron C/T 0.058 .0909 .0400
6 rs6938235 117254639 Intron G/T 0.330 .0268 .0139
7 rs17078405 117260764 Upstream A/G 0.061 .0400 .0244
8 rs339319 117295428 Upstream G/A 0.277 .6473 .0483
9 rs339321 117298883 Upstream T/C 0.276 .6769 .0400
aMAF in our sample.
bp Values in bold indicate nominal significant associations (p .05). p Values in bold italic indicate significant associations after adjusting for multiple
testing (p<.0074).
bFortheSNPrs686708,theadjustedBMDvaluesforthethreegenotypesAA,AG,andGGinthesamplesstudiedwereasfollows: 0.015,0.000,and0.022
(p¼.023);FortheSNPrs571296,theadjustedBMDvaluesforthethreegenotypesAA,AG,andGGinthesamplesstudiedwereasfollows:0.025,0.005,and
 0.012 (p¼.048).
DELETION OF GPRC6A CAUSES OSTEOPENIA Journal of Bone and Mineral Research 1099HapMap data set with Haploview software showed the existence
of extended and strong intermarker LD in the genomic region
between SNP rs571296 and SNP rs339321 (Supplemental Fig. S).
SNP rs686708 was outside the LD block and linked very weakly
with other SNPs presented (Supplemental Fig. 1).
Discussion
GPRC6A is a widely distributed member of the amino acid– and
calcium-sensing receptor family that appears to function as an
nutrient-sensing anabolic receptor.
(6) In this study we have
demonstrated direct effects of GPRC6A on regulating osteoblast
function. The predominant effect of GPRC6A deficiency in vivo
was to impair bone mineralization, which was associated with a
reduction in osteoblast gene expression markers without
changing bone-resorptive markers in vivo. We show that these
changes are due, at least in part, to direct effects of the loss of
GPRC6A in osteoblasts. In this regard, a primary GPRC6A-
dependent effect on osteoblasts is suggested by the abnormal
differentiation and attenuated response to calcium and arginine
stimulationofosteoblastsderivedfromGPRC6Anullmiceinvitro.
A direct role of GPRC6A in osteoblasts also was confirmed by
siRNA-mediated knockdown of this receptor in MC3T3-E1
osteoblasts that was associated with reduction in calcium-
stimulated ERK activation. The human relevance of these
observations is supported by the association between SNPs
rs686708 and rs571296 and reductions in spinal BMD in
Caucasians, raising the possibility that GPRC6A polymorphisms
may contribute to human osteopenia.
Several limitations of this study prevent more definitive
conclusions. First, since GPRC6A null mice represent a global
knockout of this receptor, our in vivo findings are still
confounded by the potential actions of concomitant alterations
inthe ratiooftestosterone andestrogens knowntobe presentin
thesemiceortootherundefinedsecondaryconsequencesofthe
generalized loss of GPRC6A.
(6) The absence of increased bone
resorption in GPRC6A null mice, however, along with the direct in
vitro effects of GPRC6 on osteoblast function in two different
models (GPRC6A null and GPRC6A knockdown), suggests that
direct effects from receptor loss rather than alterations in sex
hormones may account for the osteopenia in GPRC6A
 /  mice.
Indeed, testosterone deficiency typically leads to increased
osteoclast-mediated bone resorption,
(26) which was not observ-
ed in GPRC6A null mice. While the attenuation of calcium and
amino acid response in isolated osteoblasts from GPRC6A null
mice supports a direct role, further studies that compare the
effects of testosterone replacement with administration of
GPRC6A ligands (e.g., calcium, strontium, amino acids, and
osteoclacin) to restore bone mass in GPRC6A
 /  mice will be
needed to determine the relative contribution of secondary
alterations in sex hormones and primary loss of calcium-sensing
receptor responses to the observed bone phenotype in GPRC6A
null mice. Second, with regard to the role of GPRC6A in humans,
SNPs rs686708 and rs571296 are not in the coding region of
GPRC6A and therefore are not definitely the actual disease-
causing variants. Fine mapping of SNPs tightly linked to SNPs
rs686708 and rs571296 and functional studies will be required to
identify the causal variants in the GPRC6A region responsible for
human osteopenia.
Our data also support the presence of more than one calcium-
sensing mechanism in osteoblasts. Indeed, the full complement
of physiologically relevant receptors mediating the changes in
amino acids, calcium, and osteocalcin released by osteoclastic-
mediated bone resorption continues to be explored. Recent data
support a role for the amino acid– and calcium-sensing receptor
CASR in regulating osteoblast function.
(27,28) Conditional dele-
tion of the 7-TM domain of CASR using Col1-2.3-Cre results in a
severe skeletal phenotype.
(28) In addition, some studies have
implicated CASR in the differentiation of osteoblasts and growth
plate chondrocytes.
(28,29) On the other hand, the original CASR
knockout mouse model (which lacks exon 5) fails to display a
bone phenotype when hyperparathyroidism is corrected by
either performing a ‘‘molecular parathyroidectomy’’ or ablating
PTH receptor signaling.
(30,31) Also, the anabolic bone effects of
strontium ranelate on osteoblast replication and survival are
independent of CASR.
(32) The explanation for disparity in bone
phenotype between the conditional and global CASR
 /  lacking
exon 5 knockout mouse models is not clear. One possibility is
that global CASR
 /  mice lacking exon 5 are hypomorphic
owing to the persistent function of an alternatively spliced exon
5–deleted CASR in bone and cartilage. Although CASR null
osteoblasts retain their calcium-sensing capabilities, so far no
signal-transduction activity of the transfected alternatively
spliced exon 5–deleted CASR has been identified.
(33,34) Another
theoretical possibility is that the actions of cre-recombinase in
the conditional CASR model creates a secreted extracellular
domain of CASR that acts as a dominant-negative ‘‘decoy’’
receptor todisrupt CASR functioninnearby tissues. Alternatively,
the expression of GPRC6A in bone and osteoblasts and the
resulting bone phenotype raise the possibility that GPRC6A is a
candidate for another osteoblastic calcium-sensing receptor
(4,15)
that is distinct from CASR
(15) and which could account for some
of these disparate observations. The residual calcium-sensing
functions in GPRC6A null mice, after silencing of GPRC6A in
MC3T3 cells, leaves open the possibility of more than one
calcium-sensing receptor in osteoblasts.
Nevertheless, the wide expression of GPRC6A also raises the
possibility that GPRC6A could have a physiologic function in
coordinating the responses of bone with other organ systems to
changing nutritional cues. For example, there may be a
physiologic need to coordinate renal calcium excretion and
osteoblast-mediated bone formation. Theoretically, a primary
decrease inbone formation and decreased buffering capacity for
calcium, with consequent increased urinary expression of dietary
calcium, could account for the relationship between osteopenia
and hypercalciuria in GPRC6A
 /  mice. Conversely, activation of
GPRC6A would be predicted to stimulate osteoblast-mediated
bone calcium accretion and renal calcium conservation to meet
the need for bone mineralization. There are some enigmatic
clinical disorders with features similar to those of GPRC6A
 / 
mice that support the possibility of coordinated effects between
bone formation and renal conservation of calcium. In this regard,
a subset of male patients with idiopathic osteoporosis described
by Zerwekh and Pak
(35) has the combined features of decreased
osteoblast-mediated bone formation and hypercalciuria without
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abnormal vitamin D levels. Some patients with what appears to
be primary hypercalciuria and nephrolithiasis also have
concomitant low bone density and low bone turnover
(36)
without increased PTH levels that would be expected from a
sole defect in renal calcium handling. There are also examples of
primary bone defects that are associated with hypercalciuria
without increased PTH. These include osteogenesis imperfecta
type 1 caused by Col1A1 and Col1A2 mutations, infantile
hypophoshatasia caused by inactivating mutations of ALP,
and McCune-Albright syndrome caused by activating mutations
of GNAS1.
(8) It will be interesting to determine if gene
polymorphisms of GPRC6A are associated with osteopenic and
hypercalciuric clinical disorders.
These findings also expand the repertoire of GPCRs that
regulate the functional activity and provides greater insights
into the function of Gai in bone. In this regard, GPRC6A is
predominately a Gai-coupled receptor.
(4) Compared with other
well-characterized anabolic receptors, such as the PTH receptor,
which is coupled to Gas and Gaq-dependent signaling path-
ways
(37) that regulate proliferation and differentiation of
osteoblasts, these studies suggest that Gai-dependent pathways
play a distinct role in regulating osteoblast gene expression,
mainly affecting the mineralization of bone. The classica effect of
Gai activation in inhibiting adenylyl cyclase activity might be
expected to oppose signaling of Gas-coupled GPCRs in
osteoblasts.
(38) There is little available information on the role
of osteoblast signaling by Gai, but the pertussis toxin–
dependent proliferative actions of fluoride and strontium on
osteoblasts in vitro,
(4,39) Gai-coupled apelin receptor stimulation
of osteoblast proliferation in vitro.
(40) development of osteo-
porosis in Gai-coupled CB2 cannabinoid receptor knockout
mice,
(41) as well as our findings in GPRC6A null mice, suggest that
Gai signaling is important. Potential anabolic actions of Gai-
coupled receptors, including GPRC6A, might be mediated
through activation of mitogen-activated protein kinase (MAPK)
pathways.
(42)
In contrast to our studies, Wellendroph and colleagues
(16)
generated a GPRC6A null mouse by targeting exon VI of
GPRC6A, which encodes the seven transmembrane domain and
C-terminal tail. Analysis of these mice failed to identify any
skeletal abnormalities in 13-week-old mice. At present, we have
no explanation for these disparate findings, but similar to the
differences observed between existing CASR knockout models
described earlier,
(28,43) this may represent another example
where disrupting the extracellular domain results in no
expression of the GPCR, whereas disrupting the transmembrane
domain may lead to partial translation of the extracellular
domain and functional effects. Regardless, there are other
instances of multiple laboratories independently targeting the
same GPCR and failing to find similar phenotypes that have been
attributed to a variety of different mechanisms.
(44)
Insummary,wehaveshownthatGPRC6Ahasadirectfunction
in osteoblasts. The ligand profile of GPRC6A, which includes
extracellular calcium, calcimimetics, amino acids, and osteocal-
cin,
(1,2,4,45) along with the complex phenotype of GPRC6A null
mice, suggests that GPRC6A may represent an anabolic receptor
that responds to a variety of nutritional and hormonal signals
and may serve to coordinate the functions of multiple organs,
including bone, to changes in the local and systemic
concentrations of these ligands.
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